This approval expands the total count of Covid-19 vaccines authorised in the country to five. Last week, J&J submitted an application seeking Emergency Use Authorization (EUA) for its
This vaccine candidate is based on the company’s Fc fusion protein platform. It stimulates a Th1/Th2 mixed immune response against the receptor-binding domain (RBD) of the SARS-CoV-2 spike
BRII-196 and BRII-198 are non-competing monoclonal antibodies obtained from convalesced Covid-19 patients. These antibodies neutralise SARS-CoV-2. The trial is funded by the NIH unit National Institute of Allergy
German pharmaceutical firm Bayer has agreed to acquire Vividion Therapeutic to strengthen its drug discovery capabilities. Vividion Therapeutics uses novel discovery technologies to develop therapies for patients with
The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate. NVX-CoV2373 is
Amgen has announced plans to construct a new multi-product drug substance manufacturing facility in Holly Springs, North Carolina, the US. The company is committed to invest approximately $550m.
Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development. Under terms of
Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.
The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ investigational Covid-19 antibody cocktail REGEN-COV. Designed to block SARS-CoV-2 infectivity, REGEN-COV
Takeda Pharmaceutical has announced collaboration with Frazier Healthcare Partners to launch HilleVax to develop and commercialise the former’s clinical stage norovirus vaccine candidate, HIL-214 (formerly TAK-214). HIL-214 is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.